PMNs, 2 × 104 cells/ml in PBS+/+, were incubated with increasing concentrations (1 μM–0·1 nM) of the FPR2/ALX agonists (15-epi-LXA4 or compound 43) or CysTL1 antagonists (montelukast www.selleckchem.com/products/NVP-AUY922.html or MK-571) for 30 min at 37°C or vehicle (DMSO < 0·1%) in 96-well plates. Human recombinant IL-8 (100 nM) was added to the wells and incubated for 4 h. After covering the bottom of the plate with the adhesive non-translucid paper, the caspase 3/7 reagent was added

and incubated for 30 min. Caspase 3/7 activity was measured by luminometry using a Luminoskan Ascent (Thermo Labsystems, Bar Hill, Cambridge, UK). Caspase inhibitor I (5 μM) was used as a control of apoptosis inhibition and staurosporine (1 μg/ml) as a control of apoptosis induction. In order to avoid LPS contamination, fresh buffers were prepared using sterile and filtered solutions on the same day of the apoptosis assay. PMNs at 1 × 106 cells/ml in PBS+/+ were incubated with the FPR2/ALX agonists (15-epi-LXA4 and compound 43) and CysTL1 antagonists (montelukast and MK-571) (100 nM) for 30 min at 37°C or vehicle (DMSO < 0·1%) in 24-well plates. Human recombinant IL-8 (100 nM) was added to the wells and incubated for 4 h. After incubation cells were transferred to a clean FACS tube and washed with PBS (×2). Briefly, cells were resuspended with ×1 binding buffer (500 μl) and 5 μl FDA-approved Drug Library purchase of annexin V-FITC (Sigma, Saint

Louis, MO, USA) and 10 μl of propidium iodide were added. Cells were incubated

at room temperature for 10 min and fluorescence was measured immediately by flow cytometry using a FACSCanto (BD Biosciences, Franklin Lakes, NJ, USA). Dose–response curves were set up in duplicate. Half maximal inhibitory concentration (IC50) and Half maximal effective concentration (EC50) calculations O-methylated flavonoid were performed using the four-parameter logistic (4PL) non-linear regression [log (inhibitor) versus response with variable slope equation] using GraphPad Prism software. IC50 values are reported as geometric mean (GeoMean) ± standard error of the mean. Values for chemotaxis and apoptosis assessment were analysed by Student’s t-test. In order to study the signalling pathway triggered by activation of FPR2/ALX and CysLT1 by each reference compound, cAMP and GTPγ binding assays in FPR2/ALX recombinant cells and membranes and binding and calcium flux assays in CysLT1 recombinant cells were performed. IC50 and percentage of inhibition of the reference compounds in agonist and antagonist mode in FPR2/ALX and CysLT1 are shown in Table 1 and Fig. 2, respectively. 15-Epi-LXA4 was inactive (0% of inhibition at 100 μM) in either GTPγ binding or cAMP assays in both agonist or antagonist mode in FPR2/ALX-expressing cells (Table 1 and Fig. 2a). Calcium release was not increased after stimulation of FPR2/ALX recombinant cells by 15-epi-LXA4 (data not shown).